Proteasome inhibitors in acute leukemia.

Abstract

Proteasome inhibition has been recognized as a novel treatment modality in hematologic malignancies. Initially, the reversible proteasome inhibitor bortezomib demonstrated efficacy in multiple myeloma (MM), which supported its approval for relapsed and refractory MM in 2003. Later on, carfilzomib, a next-generation irreversible proteasome inhibitor was approved by the US FDA in July 2012 for relapsed/refractory MM. Currently, several other proteasome inhibitors are undergoing preclinical and clinical evaluation. The successes of proteasome inhibitors in MM are now being translated to other hematologic malignancies, including acute leukemia. The first clinical studies with bortezomib in leukemia revealed promising clinical activity, particularly when combined with conventional chemotherapeutics. In this review the position of proteasome inhibitors in acute leukemia treatment is summarized and discussed. Special focus is also attributed to immunoproteasome inhibitors. As a future perspective, it is anticipated that proteasome inhibitors may prove to be of added value in therapeutic interventions for acute leukemia.

DOI: 10.1586/era.13.4
020040020132014201520162017
Citations per Year

459 Citations

Semantic Scholar estimates that this publication has 459 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Niewerth2013ProteasomeII, title={Proteasome inhibitors in acute leukemia.}, author={Denise Niewerth and Ilse Dingjan and Jacqueline Cloos and Gerrit Jansen and Gertjan Kaspers}, journal={Expert review of anticancer therapy}, year={2013}, volume={13 3}, pages={327-37} }